At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GHRS GH Research PLC
Closed 09-19 16:00:00 EDT
7.80
-0.19
-2.38%
盘后7.80
+0.000.00%
16:01 EDT
High8.50
Low7.57
Vol52.04K
Open8.07
D1 Closing7.99
Amplitude11.64%
Mkt Cap405.82M
Tradable Cap50.58M
Total Shares52.03M
T/O413.88K
T/O Rate0.80%
Tradable Shares6.48M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
GH Research Engages Investors at Healthcare Conference
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.